Is there a Bearish outlook for Medifast Inc (NYSE:MED) this week?

September 13, 2017 - By Marie Mckinney

 Is there a Bearish outlook for Medifast Inc (NYSE:MED) this week?
Investors sentiment decreased to 1.11 in Q4 2016. Its down 0.30, from 1.41 in 2016Q3. It worsened, as 12 investors sold Medifast Inc shares while 53 reduced holdings. 19 funds opened positions while 53 raised stakes. 10.30 million shares or 1.41% more from 10.16 million shares in 2016Q3 were reported.
Deutsche Financial Bank Ag accumulated 0% or 45,648 shares. First Advsrs L P invested in 0% or 12,487 shares. Assetmark Inc has 3 shares for 0% of their portfolio. Clarivest Asset Mngmt Ltd Liability Company has invested 0.09% in Medifast Inc (NYSE:MED). Stevens Management Limited Partnership accumulated 5,919 shares or 0.01% of the stock. Ingalls & Snyder Ltd Liability Com accumulated 72,255 shares. Manufacturers Life Insurance The stated it has 7,156 shares. Pacific Ridge Cap Partners Ltd Liability Corporation accumulated 89,140 shares. Menta Limited Liability Corp accumulated 111,577 shares. State Of Alaska Department Of Revenue holds 0% of its portfolio in Medifast Inc (NYSE:MED) for 1,210 shares. 9,300 are owned by Tudor Inv Corporation Et Al. Acadian Asset Ltd Liability holds 0.09% of its portfolio in Medifast Inc (NYSE:MED) for 453,741 shares. Morgan Stanley reported 0% stake. Eqis Mngmt Incorporated accumulated 0.04% or 16,165 shares. State Of Tennessee Treasury Department holds 8,919 shares.

Medifast Inc (NYSE:MED) Ratings Coverage

Among 3 analysts covering Medifast (NYSE:MED), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Medifast had 6 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Medifast Inc (NYSE:MED) has “Buy” rating given on Monday, October 5 by Sidoti. Wunderlich initiated Medifast Inc (NYSE:MED) rating on Friday, January 29. Wunderlich has “Hold” rating and $32 target. Sidoti downgraded the stock to “Neutral” rating in Monday, November 30 report. The stock of Medifast Inc (NYSE:MED) earned “Buy” rating by Sidoti on Monday, January 11. The company was downgraded on Monday, August 10 by Zacks. DA Davidson initiated Medifast Inc (NYSE:MED) rating on Wednesday, August 16. DA Davidson has “Buy” rating and $65.0 target. Below is a list of Medifast Inc (NYSE:MED) latest ratings and price target changes.

16/08/2017 Broker: DA Davidson Rating: Buy New Target: $65.0 Initiate

About 38,909 shares traded. Medifast Inc (NYSE:MED) has risen 25.81% since September 13, 2016 and is uptrending. It has outperformed by 9.11% the S&P500.

Medifast, Inc. is engaged in the production, distribution and sale of weight loss, weight management and healthy living products, and other consumable health and nutritional products. The company has market cap of $652.82 million. Medifast product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products and vitamins. It has a 27.47 P/E ratio. The Firm provides weight loss, weight management and healthy living products and programs through multiple channels of distribution, which include Take Shape For Life; its direct to consumer business unit through its Website and in-house call centers; Franchise Medifast Weight Control Centers, and a national network of physicians.

More important recent Medifast Inc (NYSE:MED) news were published by: which released: “Medifast, Inc. Announces First Quarter 2017 Financial Results” on May 04, 2017, also published article titled: “Medifast, Inc. Announces Fourth Quarter and Full Year 2016 Financial Results”, published: “Medifast Is Overweight With Inventory. Will Margins Slim Down?” on June 01, 2017. More interesting news about Medifast Inc (NYSE:MED) was released by: and their article: “Medifast, Inc. Announces Second Quarter 2017 Financial Results” with publication date: August 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: